Renal dysfunction after total-body irradiation. Significance of selective renal shielding blocks

Strahlenther Onkol. 2005 Nov;181(11):704-8. doi: 10.1007/s00066-005-1405-8.

Abstract

Purpose: A retrospective analysis was conducted on the outcome of total-body irradiation (TBI) followed by bone marrow transplantation (BMT) on leukemia patients. Also studied was the risk of renal dysfunction after TBI/BMT with or without the use of selective renal shielding blocks.

Patients and methods: The cases of 109 leukemia patients who received TBI as a component of the conditioning regimen for their BMT were reviewed. They received 12 Gy of TBI in six fractions over 3 consecutive days. Doses to eyes and lungs were reduced to 7 Gy and 8 Gy, respectively, by customized organ shielding blocks. After March 1999, renal shielding blocks were used to constrain the renal dose to 10 Gy. The patients were followed for a median period of 16.6 months (range: 0.3-180.1 months).

Results: The 2-year and 5-year overall survival rates were 55.4% and 43.2%, respectively. Renal dysfunction-free rates were different between those with and without renal shielding blocks: 100% and 78.5%, respectively, at 2 years. Overall survivals were not significantly different among these patients: 60.4% and 52.9%, respectively, at 2 years in patients with and without renal shielding blocks (p = 0.53).

Conclusion: The use of selective renal shielding blocks provided evidence for reducing radiation-induced renal toxicities without decreasing the overall survival rate.

MeSH terms

  • Adolescent
  • Adult
  • Bone Marrow Transplantation*
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Female
  • Humans
  • Kidney / radiation effects*
  • Leukemia / mortality
  • Leukemia / radiotherapy*
  • Leukemia / surgery
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / radiotherapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / radiotherapy
  • Leukemia, Myeloid, Acute / surgery
  • Male
  • Middle Aged
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • Retrospective Studies
  • Survival Analysis
  • Whole-Body Irradiation* / adverse effects